Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4576 AL 4590

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Wattmo C, Minthon L, Wallin ÅK.

Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1.

Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders

Godefroy O, Bakchine S, Verny M, Delabrousse-Mayoux JP, Roussel M, Pere JJ; REFLEX study group:.

J Alzheimers Dis. 2016;51(3):815-25. doi: 10.3233/JAD-150971.

Pseudobulbar Affect or Depression in Dementia?

Chang YD, Davis MP, Smith J, Gutgsell T.

J Pain Symptom Manage. 2016 May;51(5):954-8. doi: 10.1016/j.jpainsymman.2015.12.321. Epub 2016 Feb 17.

Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease

Han SH, Lee JH, Kim SY, Park KW, Chen C, Tripathi M, Dash A, Kubota N.

Acta Neurol Scand. 2017 Feb;135(2):252-256. doi: 10.1111/ane.12571. Epub 2016 Feb 29.

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease

Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, Fox NC, Ketter N, Liu E, Ryan JM; ACC-001 (QS-21) Study Team.

J Alzheimers Dis. 2016;51(4):1131-43. doi: 10.3233/JAD-150376.

Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study

Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.

J Alzheimers Dis. 2016;51(4):1237-47. doi: 10.3233/JAD-150978.

Diabetes and Alzheimer's disease crosstalk

Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM.

Neurosci Biobehav Rev. 2016 May;64:272-87. doi: 10.1016/j.neubiorev.2016.03.005. Epub 2016 Mar 9.

Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy

Paterson RW, Abdi Z, Haines A, Schott JM.

Clin Neurol Neurosurg. 2016 May;144:64-6. doi: 10.1016/j.clineuro.2016.02.036. Epub 2016 Mar 3.

Detection of Aβ Monomers and Oligomers: Early Diagnosis of Alzheimer's Disease

Zhou Y, Liu L, Hao Y, Xu M.

Chem Asian J. 2016 Mar 18;11(6):805-17. doi: 10.1002/asia.201501355. Epub 2016 Feb 4.

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Xu MM, Ren WM, Tang XC, Hu YH, Zhang HY.

Acta Pharmacol Sin. 2016 Jun;37(6):719-30. doi: 10.1038/aps.2015.155. Epub 2016 Mar 21.

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)

Zhang ZX, Hong Z, Wang YP, He L, Wang N, Zhao ZX, Zhao G, Shang L, Weisskopf M, Callegari F, Strohmaier C.

CNS Neurosci Ther. 2016 Jun;22(6):488-96. doi: 10.1111/cns.12521. Epub 2016 Mar 25.

Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease

Darvesh S.

Curr Alzheimer Res. 2016;13(10):1173-7. doi: 10.2174/1567205013666160404120542.

[Methylphenidate in a patient with Alzheimer's disease : Increase in drive and cardiac performance]

Schuhfried G, Schuhfried G.

Z Gerontol Geriatr. 2017 Jun;50(4):362-364. doi: 10.1007/s00391-016-1043-z. Epub 2016 Apr 13.

Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition

Kantarci K, Lowe VJ, Lesnick TG, Tosakulwong N, Bailey KR, Fields JA, Shuster LT, Zuk SM, Senjem ML, Mielke MM, Gleason C, Jack CR, Rocca WA, Miller VM.

J Alzheimers Dis. 2016 May 7;53(2):547-56. doi: 10.3233/JAD-160258.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias